Pegcetacoplan demonstrates sustained 52-week efficacy and safety across subgroups in C3G and primary IC-MPGN: results from the VALIANT trial

Fakhouri, Fadi and Nester, Carla and Bomback, Andrew and Ariceta, Gema and Delmas, Yahsou and Dixon, Bradley and Gale, Daniel and Greenbaum, Larry and Han, Seung Hyeok and Isbel, Nicole and Licht, Christoph and Mastrangelo, Antonio and Mizuno, Masashi and de Holanda, Maria Izabel Neves and Pickering, Matthew and Remuzzi, Giuseppe and Van De Kar, Nicole and Vivarelli, Marina and Walker, Patrick and Wallace, Dean and Zecher, Daniel and Le Quintrec, Moglie and Borovitz, Yael and Melhem, Nabil and Gordon, Katie and Mukherjee, Anwesha and Szamosi, Johan and Quintana-Gallardo, Lucia (2025) Pegcetacoplan demonstrates sustained 52-week efficacy and safety across subgroups in C3G and primary IC-MPGN: results from the VALIANT trial. SWISS MEDICAL WEEKLY, 155 (11). SO23. ISSN 1424-7860, 1424-3997

Full text not available from this repository.
Item Type: Article
Subjects: 600 Technology > 610 Medical sciences Medicine
Divisions: Medicine > Lehrstuhl für Innere Medizin II
Depositing User: Dr. Gernot Deinzer
Date Deposited: 12 Aug 2026 05:12
Last Modified: 12 Aug 2026 05:12
URI: https://pred.uni-regensburg.de/id/eprint/67836

Actions (login required)

View Item View Item
pred is powered by EPrints 3.4 which is developed by the School of Electronics and Computer Science at the University of Southampton. More information and software credits.